Amantadine and other antiglutamate agents
Identifieur interne : 002644 ( PascalFrancis/Corpus ); précédent : 002643; suivant : 002645Amantadine and other antiglutamate agents
Auteurs :Source :
- Movement disorders [ 0885-3185 ] ; 2002.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
---|
Format Inist (serveur)
NO : | PASCAL 02-0472057 INIST |
---|---|
ET : | Amantadine and other antiglutamate agents |
AU : | GOETZ (C. G.); KOLLER (W. C.); POEWE (W.); RASCOL (O.); SAMPAIO (C.); BRIN (M. F.); LEES (A. J.); LEWITT (P.); LOZANO (A.); MIZUNO (Y.); NUTT (J.); OERTEL (W.); OLANOW (C. W.); TOLOSA (E.); BREFEL-COURBON (C.); EICHHORN (T.); FERREIRA (J.); KATZENSCHLAGER (R.); LUGINGER (E.); PASTOR (P.); SEPPI (K.); SPIEKER (S.); PEARLMAN (S.) |
AF : | Movement Disorder Society/Milwaukee, WI/Etats-Unis |
DT : | Publication en série; Niveau analytique |
SO : | Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. SUP4; S13-S22; Bibl. 1 p.1/4 |
LA : | Anglais |
CC : | 002B02B06 |
FD : | Parkinson maladie; Amantadine; Chimiothérapie; Antiparkinsonien; Agoniste; Récepteur dopaminergique; Stimulant dopaminergique; Antagoniste; Récepteur NMDA; Récepteur glutamate; Médecine factuelle; Toxicité; Traitement adjuvant; Article synthèse; Prévention; Homme |
FG : | Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative |
ED : | Parkinson disease; Amantadine; Chemotherapy; Antiparkinson agent; Agonist; Dopamine receptor; Dopamine agonist; Antagonist; NMDA receptor; Glutamate receptor; Evidence-based medicine; Toxicity; Adjuvant treatment; Review; Prevention; Human |
EG : | Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease |
SD : | Parkinson enfermedad; Amantadina; Quimioterapia; Antiparkinsoniano; Agonista; Receptor dopaminérgico; Estimulante dopaminérgico; Antagonista; Receptor NMDA; Receptor glutámato; Medicina basada en pruebas; Toxicidad; Tratamiento adyuvante; Artículo síntesis; Prevención; Hombre |
LO : | INIST-20953.354000108923890020 |
ID : | 02-0472057 |
Links to Exploration step
Pascal:02-0472057Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Amantadine and other antiglutamate agents</title>
<author><name sortKey="Goetz, C G" sort="Goetz, C G" uniqKey="Goetz C" first="C. G." last="Goetz">C. G. Goetz</name>
<affiliation><inist:fA14 i1="01" i2="1"><s1>Movement Disorder Society</s1>
<s2>Milwaukee, WI</s2>
<s3>USA</s3>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Koller, W C" sort="Koller, W C" uniqKey="Koller W" first="W. C." last="Koller">W. C. Koller</name>
</author>
<author><name sortKey="Poewe, W" sort="Poewe, W" uniqKey="Poewe W" first="W." last="Poewe">W. Poewe</name>
</author>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name>
</author>
<author><name sortKey="Sampaio, C" sort="Sampaio, C" uniqKey="Sampaio C" first="C." last="Sampaio">C. Sampaio</name>
</author>
<author><name sortKey="Brin, M F" sort="Brin, M F" uniqKey="Brin M" first="M. F." last="Brin">M. F. Brin</name>
</author>
<author><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A. J." last="Lees">A. J. Lees</name>
</author>
<author><name sortKey="Lewitt, P" sort="Lewitt, P" uniqKey="Lewitt P" first="P." last="Lewitt">P. Lewitt</name>
</author>
<author><name sortKey="Lozano, A" sort="Lozano, A" uniqKey="Lozano A" first="A." last="Lozano">A. Lozano</name>
</author>
<author><name sortKey="Mizuno, Y" sort="Mizuno, Y" uniqKey="Mizuno Y" first="Y." last="Mizuno">Y. Mizuno</name>
</author>
<author><name sortKey="Nutt, J" sort="Nutt, J" uniqKey="Nutt J" first="J." last="Nutt">J. Nutt</name>
</author>
<author><name sortKey="Oertel, W" sort="Oertel, W" uniqKey="Oertel W" first="W." last="Oertel">W. Oertel</name>
</author>
<author><name sortKey="Olanow, C W" sort="Olanow, C W" uniqKey="Olanow C" first="C. W." last="Olanow">C. W. Olanow</name>
</author>
<author><name sortKey="Tolosa, E" sort="Tolosa, E" uniqKey="Tolosa E" first="E." last="Tolosa">E. Tolosa</name>
</author>
<author><name sortKey="Brefel Courbon, C" sort="Brefel Courbon, C" uniqKey="Brefel Courbon C" first="C." last="Brefel-Courbon">C. Brefel-Courbon</name>
</author>
<author><name sortKey="Eichhorn, T" sort="Eichhorn, T" uniqKey="Eichhorn T" first="T." last="Eichhorn">T. Eichhorn</name>
</author>
<author><name sortKey="Ferreira, J" sort="Ferreira, J" uniqKey="Ferreira J" first="J." last="Ferreira">J. Ferreira</name>
</author>
<author><name sortKey="Katzenschlager, R" sort="Katzenschlager, R" uniqKey="Katzenschlager R" first="R." last="Katzenschlager">R. Katzenschlager</name>
</author>
<author><name sortKey="Luginger, E" sort="Luginger, E" uniqKey="Luginger E" first="E." last="Luginger">E. Luginger</name>
</author>
<author><name sortKey="Pastor, P" sort="Pastor, P" uniqKey="Pastor P" first="P." last="Pastor">P. Pastor</name>
</author>
<author><name sortKey="Seppi, K" sort="Seppi, K" uniqKey="Seppi K" first="K." last="Seppi">K. Seppi</name>
</author>
<author><name sortKey="Spieker, S" sort="Spieker, S" uniqKey="Spieker S" first="S." last="Spieker">S. Spieker</name>
</author>
<author><name sortKey="Pearlman, S" sort="Pearlman, S" uniqKey="Pearlman S" first="S." last="Pearlman">S. Pearlman</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">02-0472057</idno>
<date when="2002">2002</date>
<idno type="stanalyst">PASCAL 02-0472057 INIST</idno>
<idno type="RBID">Pascal:02-0472057</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002644</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Amantadine and other antiglutamate agents</title>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2002">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvant treatment</term>
<term>Agonist</term>
<term>Amantadine</term>
<term>Antagonist</term>
<term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Dopamine agonist</term>
<term>Dopamine receptor</term>
<term>Evidence-based medicine</term>
<term>Glutamate receptor</term>
<term>Human</term>
<term>NMDA receptor</term>
<term>Parkinson disease</term>
<term>Prevention</term>
<term>Review</term>
<term>Toxicity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Amantadine</term>
<term>Chimiothérapie</term>
<term>Antiparkinsonien</term>
<term>Agoniste</term>
<term>Récepteur dopaminergique</term>
<term>Stimulant dopaminergique</term>
<term>Antagoniste</term>
<term>Récepteur NMDA</term>
<term>Récepteur glutamate</term>
<term>Médecine factuelle</term>
<term>Toxicité</term>
<term>Traitement adjuvant</term>
<term>Article synthèse</term>
<term>Prévention</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>17</s2>
</fA05>
<fA06><s3>SUP4</s3>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Amantadine and other antiglutamate agents</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Management of Parkinson's disease: an evidence-based review</s1>
</fA09>
<fA12 i1="01" i2="1"><s1>GOETZ (C. G.)</s1>
</fA12>
<fA12 i1="02" i2="1"><s1>KOLLER (W. C.)</s1>
</fA12>
<fA12 i1="03" i2="1"><s1>POEWE (W.)</s1>
</fA12>
<fA12 i1="04" i2="1"><s1>RASCOL (O.)</s1>
</fA12>
<fA12 i1="05" i2="1"><s1>SAMPAIO (C.)</s1>
</fA12>
<fA12 i1="06" i2="1"><s1>BRIN (M. F.)</s1>
</fA12>
<fA12 i1="07" i2="1"><s1>LEES (A. J.)</s1>
</fA12>
<fA12 i1="08" i2="1"><s1>LEWITT (P.)</s1>
</fA12>
<fA12 i1="09" i2="1"><s1>LOZANO (A.)</s1>
</fA12>
<fA12 i1="10" i2="1"><s1>MIZUNO (Y.)</s1>
</fA12>
<fA12 i1="11" i2="1"><s1>NUTT (J.)</s1>
</fA12>
<fA12 i1="12" i2="1"><s1>OERTEL (W.)</s1>
</fA12>
<fA12 i1="13" i2="1"><s1>OLANOW (C. W.)</s1>
</fA12>
<fA12 i1="14" i2="1"><s1>TOLOSA (E.)</s1>
</fA12>
<fA12 i1="15" i2="1"><s1>BREFEL-COURBON (C.)</s1>
</fA12>
<fA12 i1="16" i2="1"><s1>EICHHORN (T.)</s1>
</fA12>
<fA12 i1="17" i2="1"><s1>FERREIRA (J.)</s1>
</fA12>
<fA12 i1="18" i2="1"><s1>KATZENSCHLAGER (R.)</s1>
</fA12>
<fA12 i1="19" i2="1"><s1>LUGINGER (E.)</s1>
</fA12>
<fA12 i1="20" i2="1"><s1>PASTOR (P.)</s1>
</fA12>
<fA12 i1="21" i2="1"><s1>SEPPI (K.)</s1>
</fA12>
<fA12 i1="22" i2="1"><s1>SPIEKER (S.)</s1>
</fA12>
<fA12 i1="23" i2="1"><s1>PEARLMAN (S.)</s1>
</fA12>
<fA18 i1="01" i2="1"><s1>Movement Disorder Society</s1>
<s2>Milwaukee, WI</s2>
<s3>USA</s3>
</fA18>
<fA20><s2>S13-S22</s2>
</fA20>
<fA21><s1>2002</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000108923890020</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2002 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>1 p.1/4</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>02-0472057</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Amantadine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Amantadine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Amantadina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Agonist</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Agonista</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Récepteur dopaminergique</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Dopamine receptor</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Receptor dopaminérgico</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Dopamine agonist</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Antagoniste</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Antagonist</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Antagonista</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Récepteur NMDA</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>NMDA receptor</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Receptor NMDA</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Récepteur glutamate</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Glutamate receptor</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Receptor glutámato</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Médecine factuelle</s0>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Evidence-based medicine</s0>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Medicina basada en pruebas</s0>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>16</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>16</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>16</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Traitement adjuvant</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Adjuvant treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Tratamiento adyuvante</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Article synthèse</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Review</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Artículo síntesis</s0>
<s5>18</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Prévention</s0>
<s5>19</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Prevention</s0>
<s5>19</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Prevención</s0>
<s5>19</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fN21><s1>273</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 02-0472057 INIST</NO>
<ET>Amantadine and other antiglutamate agents</ET>
<AU>GOETZ (C. G.); KOLLER (W. C.); POEWE (W.); RASCOL (O.); SAMPAIO (C.); BRIN (M. F.); LEES (A. J.); LEWITT (P.); LOZANO (A.); MIZUNO (Y.); NUTT (J.); OERTEL (W.); OLANOW (C. W.); TOLOSA (E.); BREFEL-COURBON (C.); EICHHORN (T.); FERREIRA (J.); KATZENSCHLAGER (R.); LUGINGER (E.); PASTOR (P.); SEPPI (K.); SPIEKER (S.); PEARLMAN (S.)</AU>
<AF>Movement Disorder Society/Milwaukee, WI/Etats-Unis</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. SUP4; S13-S22; Bibl. 1 p.1/4</SO>
<LA>Anglais</LA>
<CC>002B02B06</CC>
<FD>Parkinson maladie; Amantadine; Chimiothérapie; Antiparkinsonien; Agoniste; Récepteur dopaminergique; Stimulant dopaminergique; Antagoniste; Récepteur NMDA; Récepteur glutamate; Médecine factuelle; Toxicité; Traitement adjuvant; Article synthèse; Prévention; Homme</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative</FG>
<ED>Parkinson disease; Amantadine; Chemotherapy; Antiparkinson agent; Agonist; Dopamine receptor; Dopamine agonist; Antagonist; NMDA receptor; Glutamate receptor; Evidence-based medicine; Toxicity; Adjuvant treatment; Review; Prevention; Human</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease</EG>
<SD>Parkinson enfermedad; Amantadina; Quimioterapia; Antiparkinsoniano; Agonista; Receptor dopaminérgico; Estimulante dopaminérgico; Antagonista; Receptor NMDA; Receptor glutámato; Medicina basada en pruebas; Toxicidad; Tratamiento adyuvante; Artículo síntesis; Prevención; Hombre</SD>
<LO>INIST-20953.354000108923890020</LO>
<ID>02-0472057</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002644 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002644 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:02-0472057 |texte= Amantadine and other antiglutamate agents }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |